Cargando…

An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats

BACKGROUND: Injectable in situ gel (ISG) systems suffer from high initial drug release that may result in toxic effects. OBJECTIVE: This work aimed to develop an injectable sustained release rosuvastatin (RSV) ISG formulation with minimum initial drug burst and improved hyperlipidemic efficacy. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Tarek A, Mussari, Mohammed A, Abdel-Hady, Seham El-Sayed, El-Say, Khalid M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904902/
https://www.ncbi.nlm.nih.gov/pubmed/31839704
http://dx.doi.org/10.2147/DDDT.S224442
_version_ 1783478073507708928
author Ahmed, Tarek A
Mussari, Mohammed A
Abdel-Hady, Seham El-Sayed
El-Say, Khalid M
author_facet Ahmed, Tarek A
Mussari, Mohammed A
Abdel-Hady, Seham El-Sayed
El-Say, Khalid M
author_sort Ahmed, Tarek A
collection PubMed
description BACKGROUND: Injectable in situ gel (ISG) systems suffer from high initial drug release that may result in toxic effects. OBJECTIVE: This work aimed to develop an injectable sustained release rosuvastatin (RSV) ISG formulation with minimum initial drug burst and improved hyperlipidemic efficacy. METHODS: Six formulation factors that affect RSV release after 0.5, 2 and 24 hrs have been screened and the significant ones were optimized utilizing an experimental design tool. The optimum ISG formulation components were physicochemically characterized. Kinetic treatment, dissolution efficiency and mean dissolution time were investigated for the developed ISG formulations. Pharmacodynamic effects of the optimized ISG formulation were studied and compared to ISG formulation loaded with free RSV and to a marketed oral drug product. RESULTS: The concentration polylactide-co-ε-caprolactone (25: 75), the surfactant hydrophilic lipophilic balance (HLB) and the ratio of surfactant to polyethylene glycol 400 were significantly affecting the release of RSV during the first 24 h. Physicochemical characterization demonstrated complete dispersion of RSV in the polymeric matrix with slight changes in the drug crystalline structure. The optimized formulation demonstrated acceptable syringeability, good flow rate and was able to extend the in vitro drug release for 34 days. The ISG formulations complied with Weibull model. Pharmacodynamic study revealed a sustained reduction in the lipid profile that lasted for 21 days with a marked decrease in the lipid level during the first 24 hrs from the ISG system loaded with free RSV. CONCLUSION: The optimized RSV ISG formulation could be considered a promising strategy due to a reduction in dosing frequency and enhancement in hypolipidemic efficacy.
format Online
Article
Text
id pubmed-6904902
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69049022019-12-13 An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats Ahmed, Tarek A Mussari, Mohammed A Abdel-Hady, Seham El-Sayed El-Say, Khalid M Drug Des Devel Ther Original Research BACKGROUND: Injectable in situ gel (ISG) systems suffer from high initial drug release that may result in toxic effects. OBJECTIVE: This work aimed to develop an injectable sustained release rosuvastatin (RSV) ISG formulation with minimum initial drug burst and improved hyperlipidemic efficacy. METHODS: Six formulation factors that affect RSV release after 0.5, 2 and 24 hrs have been screened and the significant ones were optimized utilizing an experimental design tool. The optimum ISG formulation components were physicochemically characterized. Kinetic treatment, dissolution efficiency and mean dissolution time were investigated for the developed ISG formulations. Pharmacodynamic effects of the optimized ISG formulation were studied and compared to ISG formulation loaded with free RSV and to a marketed oral drug product. RESULTS: The concentration polylactide-co-ε-caprolactone (25: 75), the surfactant hydrophilic lipophilic balance (HLB) and the ratio of surfactant to polyethylene glycol 400 were significantly affecting the release of RSV during the first 24 h. Physicochemical characterization demonstrated complete dispersion of RSV in the polymeric matrix with slight changes in the drug crystalline structure. The optimized formulation demonstrated acceptable syringeability, good flow rate and was able to extend the in vitro drug release for 34 days. The ISG formulations complied with Weibull model. Pharmacodynamic study revealed a sustained reduction in the lipid profile that lasted for 21 days with a marked decrease in the lipid level during the first 24 hrs from the ISG system loaded with free RSV. CONCLUSION: The optimized RSV ISG formulation could be considered a promising strategy due to a reduction in dosing frequency and enhancement in hypolipidemic efficacy. Dove 2019-12-03 /pmc/articles/PMC6904902/ /pubmed/31839704 http://dx.doi.org/10.2147/DDDT.S224442 Text en © 2019 Ahmed et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ahmed, Tarek A
Mussari, Mohammed A
Abdel-Hady, Seham El-Sayed
El-Say, Khalid M
An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats
title An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats
title_full An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats
title_fullStr An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats
title_full_unstemmed An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats
title_short An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats
title_sort optimized surfactant-based peg-plcl in situ gel formulation for enhanced activity of rosuvastatin in poloxamer-induced hyperlipidemic rats
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904902/
https://www.ncbi.nlm.nih.gov/pubmed/31839704
http://dx.doi.org/10.2147/DDDT.S224442
work_keys_str_mv AT ahmedtareka anoptimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats
AT mussarimohammeda anoptimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats
AT abdelhadysehamelsayed anoptimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats
AT elsaykhalidm anoptimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats
AT ahmedtareka optimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats
AT mussarimohammeda optimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats
AT abdelhadysehamelsayed optimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats
AT elsaykhalidm optimizedsurfactantbasedpegplclinsitugelformulationforenhancedactivityofrosuvastatininpoloxamerinducedhyperlipidemicrats